Rezolute, Inc.

REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026.

Rezolute, Inc. (NASDAQ: RZLT - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.89 and traded as high as $4.13. Rezolute shares last traded at $4.01, with a volume of 919,233 shares changing hands. Wall Street Analyst Weigh In A number

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences: Event: Guggenheim 3rd Annual Healthcare Innovation Conference Date: November 9-11, 2026 Fireside Date/Time: Monday, November 9th at 9:00am ET Event: Jefferies Londo…

Rezolute, Inc. (NASDAQ: RZLT - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $3.84 and traded as low as $3.73. Rezolute shares last traded at $3.82, with a volume of 1,543,500 shares traded. Analyst Upgrades and Downgrades

Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.

Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have assigned a buy recommendation to the company.

Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 4,099 call options on the company. This is an increase of 618% compared to the average daily volume of 571 call options. Institutional Inflows and Outflows A number of hedge funds and other institutional investors

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.

Shares of Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have assigned a buy recommendation to the

Data from the Phase 3 sunRIZE study remains under review by FDA  The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) …

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Bank of America Corp DE reduced its stake in Rezolute, Inc. (NASDAQ: RZLT) by 31.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,970,549 shares of the company's stock after selling 1,354,699 shares during the period. Bank of America Corp